Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.

Centre Hospitalier Universitaire Dijon61 enrolled

Overview

Atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. In addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming. A non-invasive marker of this immune reprogramming has yet to be identified. Through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method. This monocentric interventional study will take place at the Dijon Bourgogne University Hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". The duration of participation in this study is 1 month. This study is based on usually performed procedures. Only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Coronary Atherosclerosis

Interventions

Blood samples

Data collectionOTHER

pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Person who provides oral consent Group 1: \- Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation Group 2: * Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation * No coronary lesion * No peripheral arterial disease (limbs, carotids, aortic aneurysm) Exclusion Criteria: * Person not affiliated with national health care system * Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * Person under a legal protection measure (curatorship, guardianship, tutorship) * Pregnant, parturient or breastfeeding women * Major unable to express consent * Minor

Outcomes

Primary Outcomes

Mitophagy level by flow cytometry

Average fluorescence corresponding to PINK1-AF488 intracellular labelling (mitophagy checkpoint) in conventional (CD33+, CD66b-, CD14++, CD16-), intermediate (CD33+, CD66-, CD14++, CD16+), or non-conventional (CD33+, CD66b-, CD14+, CD16++) monocytes.

Time frame: Before the introduction of extracorporeal circulation.